Страна: Европейски съюз
Език: английски
Източник: EMA (European Medicines Agency)
pegaspargase
Baxalta Innovations GmbH
L01XX24
pegaspargase
Antineoplastic agents,
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.,
Revision: 6
Authorised
2016-01-14
44 B. PACKAGE LEAFLET 45 PACKAGE LEAFLET: INFORMATION FOR THE USER ONCASPAR 750 U/ML SOLUTION FOR INJECTION/INFUSION pegaspargase This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Oncaspar is and what it is used for 2. What you need to know before you are given Oncaspar 3. How Oncaspar is given 4. Possible side effects 5. How to store Oncaspar 6. Contents of the pack and other information 1. WHAT ONCASPAR IS AND WHAT IT IS USED FOR Oncaspar contains pegaspargase, which is an enzyme (asparaginase) that breaks down asparagine, an important building block of proteins without which cells cannot survive. Normal cells can make asparagine for themselves, while some cancer cells cannot. Oncaspar lowers asparagine level in blood cancer cells and stops the cancer cells growing. Oncaspar is used to treat acute lymphoblastic leukaemia (ALL) in children from birth to 18 years and adults. ALL is a white blood cell cancer type in which certain immature white cells (named lymphoblasts) start growing out of control thus preventing the production of functional blood cells. Oncaspar is used together with other medicines. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ONCASPAR DO NOT USE ONCASPAR: - if you are allergic to pegaspargase or to any of the other ingredients of this medicine (listed in section 6). - if you ever had pancreatitis. - if you ever had severe bleeding following asparaginase therapy. - if you ever had blood clots following asparaginase therapy. Tell yo Прочетете целия документ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Oncaspar 750 U/ml solution for injection/infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of solution contains 750 Units (U)** of pegaspargase*. One vial of 5 ml solution contains 3,750 Units. * The active substance is a covalent conjugate of _Escherichia coli_ -derived L-asparaginase with monomethoxypolyethylene glycol **One unit is defined as the quantity of enzyme required to liberate 1 µmol ammonia per minute at pH 7.3 and 37°C The potency of this medicinal product should not be compared to the one of another pegylated or non-pegylated protein of the same therapeutic class. For more information, see section 5.1. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection/infusion. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oncaspar should be prescribed and administered by physicians and/or health care personnel experienced in the use of antineoplastic products. It should only be given in a hospital setting where appropriate resuscitation equipment is available. Patients should be closely monitored and carefully observed for any adverse reactions throughout the administration period (see section 4.4). Posology Oncaspar is usually administered as part of combination chemotherapy protocols with other antineoplastic agents (see also section 4.5). _Paediatric patients and adults ≤21 years _ The recommended dose in patients with a body surface area (BSA) ≥0.6 m 2 and who are ≤ Прочетете целия документ